The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This scoping review examined the human gut microbiota and its relation to glucose metabolism, insulin resistance, and type 2 diabetes risk. The authors searched PubMed and screened 5983 records down to 45 original observational studies. They focused on identifying key bacterial taxa associated with markers and stages of glucose dysregulation, independent of overweight, obesity, and metabolic drugs. The review also considered the potential mediating role of short-chain fatty acids (SCFAs) and the influence of diet and diet-microbiota derived metabolites.
Who was studied?
The review drew on human observational studies conducted in healthy adults as well as adults with metabolic disease and associated risk factors. Rather than a single cohort, the evidence base was pooled across 45 separate original studies identified from the PubMed literature. Specific sample sizes or demographic details for individual cohorts are not given in the abstract.
What were the most important findings?
Across the reviewed studies, alpha diversity and 45 distinct bacterial taxa were associated with glucose metabolism outcomes. Six taxa emerged as most frequently linked to glucose metabolism, including Akkermansia muciniphila, Bifidobacterium longum, the Clostridium leptum group, and Faecalibacterium prausnitzii. The authors present evidence supporting SCFAs as a mechanism that may mediate the relationship between these gut bacteria and glucose regulation. Diet and microbiota-derived metabolites are also highlighted as relevant contributors to these associations.
What are the greatest implications of this study?
Identifying specific gut bacteria, including SCFA-associated and anti-inflammatory commensals such as Faecalibacterium prausnitzii, consistently linked to glucose metabolism could open new avenues for type 2 diabetes prevention. Because these associations were found independent of obesity and metabolic drug use, the gut microbiota may represent an independent target for intervention. The proposed role of SCFAs and diet-derived metabolites suggests that dietary strategies aimed at shaping the microbiota could be a practical entry point for future prevention efforts. Overall, the findings support further mechanistic and interventional research into these key taxa and their metabolic products.